key: cord-0793984-za316vth
authors: Torres, Montserrat; Casado, Guiomar; Vigón, Lorena; Rodríguez-Mora, Sara; Mateos, Elena; Ramos-Martín, Fernando; López-Wolf, Daniel; Sanz-Moreno, José; Ryan-Murua, Pablo; Taboada-Martínez, María Luisa; López-Huertas, María Rosa; Cervero, Miguel; Coiras, Mayte
title: Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D
date: 2022-04-14
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2022.112965
sha: 8da296394217276dc28c9a955f697c17428ae8d0
doc_id: 793984
cord_uid: za316vth

Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.8 ng/mL (SD: 6.18) to test antiviral efficacy, tolerance and safety of 10,000 IU/day of cholecalciferol (vitamin D(3)) for 14 days, in comparison with 2,000 IU/day. After supplementation, mean serum 25(OH)D levels increased to 19 ng/mL on average in 2,000 IU/day versus 29 ng/mL in 10,000 IU/day group (p <0.0001). Although levels of inflammatory cytokines were not modified by treatment with 10,000 IU/day, there was an increase of anti-inflammatory cytokine IL-10 and higher levels of CD4+ T cells, with predominance of T central memory subpopulation. Cytotoxic response against pseudotyped SARS-CoV-2 infected cells was increased more than 4-fold in patients who received 10,000 IU/day. Moreover, levels of IFNγ were significantly higher in this group. Beneficial effect of supplementation with 10,000 IU/day was also observed in participants who developed ARDS and stayed at the hospital for 8.0 days, whereas those who received 2,000 IU/day stayed for 29.2 days (p=0.0381). Administration of high doses of vitamin D(3) as adjuvant of the standard care treatment during hospitalization for COVID-19 may improve the inflammatory environment and cytotoxic response against pseudotyped SARS-CoV-2 infected cells, shortening the hospital stay and, possibly, improving the prognosis.

In December 2019, several viral pneumonia cases of unknown origin were The host receptor for SARS-CoV-2 entry into intestinal and alveolar cells is angiotensin converting enzyme 2 (ACE2), and the subsequent dysregulation of the renin-angiotensin system (RAS) may lead to a massive cytokine activation, known as cytokine storm. This is a life-threatening syndrome characterized by high-level activation of immune cells and excessive production of a large number of inflammatory cytokines and chemical mediators 3, 4 , ultimately resulting in prospective fatal ARDS. Individuals with severe presentations of COVID-19 show high levels of proinflammatory cytokines such as interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF) that may interfere with the cytotoxic response of Natural Killer (NK) and CD8+ T cells by reducing the production of granzymes and perforins 5, 6 , as well as lymphopenia, mainly of CD4+ T lymphocytes and NK cells that also show an exhausted phenotype 7, 8 . Moreover, individuals with severe COVID-19 present an impaired antiviral immune response as a consequence of reduced levels of cytokines with antiviral activity such as interferons (IFN) 9 .

For a long time, there was no clinically proven specific treatment for COVID-19 10 . Supportive treatment, including oxygen and conservative fluid therapy, remains the most important strategy for patient management 2, 11 . Drugs designed for other viral infections (e.g. remdesivir), used in rheumatology (e.g. baricitinib) and humanized monoclonal IL-6R antibodies (e.g. tocilizumab) were some of the options that were assayed, but none proved to have a decisive beneficial effect 12, 13 , except for unspecific treatments to control the excessive inflammatory immune responses such as J o u r n a l P r e -p r o o f corticosteroids 14 . Recently, FDA authorized the oral administration of molnupiravir for the treatment of mild-to-moderate COVID-19 in adults, as well as nirmatrelvir and ritonavir for children and adults, but only in case of emergency for those individuals with high risk to progress to severe disease 15, 16 .

It is still undetermined why some patients show an asymptomatic disease whereas other individuals require invasive mechanical ventilation and admission to the Intensive Care Unit (ICU). The development of these severe and critical forms of COVID-19 have been associated with some predisposing factors such as obesity, hypertension and diabetes 17 . Other factor that has also been related to an increased risk of dying from COVID-19 is vitamin D deficiency. In fact, several reports have described an association between serum levels of 25-hydroxyvitamin D [25(OH)D] below 20 ng/mL (50nmol/L), and concomitant diseases, including systemic infection [18] [19] [20] [21] . Vitamin D exerts an immunomodulatory role by promoting the development of an anti-inflammatory environment. Besides, it has been described that vitamin D stimulates ACE2 that may bind to SARS-CoV-2, preventing it from attaching to ACE2 receptors and infecting the target cells [22] [23] [24] . Moreover, some studies described that vitamin D insufficiency during COVID-19 may compromise the respiratory immune response, thereby increasing the risk of severity and mortality 25 , and that there is a correlation between the vitamin D levels and the severity of the disease 26, 27 . However, there is still no clear evidence that vitamin D supplementation can prevent the severity and/or mortality of COVID-19.

In this study, we evaluated whether vitamin D supplementation to avoid its insufficiency during COVID-19 may influence positively the disease progression by reducing the levels of pro-inflammatory cytokines and increasing the cytotoxic antiviral response. Therefore, we analyzed the changes in the immune response of individuals J o u r n a l P r e -p r o o f with COVID-19 who were recruited for a randomized clinical trial to receive a moderate dose of 2,000 International Units (IU)/daily of cholecalciferol or a higher dose of 10,000 IU/daily for 14 days, in combination with the standard drug therapeutic regimen. The efficacy of both treatments at reducing the duration and severity of COVID-19 was analyzed.

This study was a multicenter, single blind, prospective, randomized clinical trial to evaluate the effect of cholecalciferol (vitamin D) supplementation in combination with the standard drug regimen therapeutic in patients hospitalized with pneumonia due to COVID-19. For ethical reasons, it was not felt possible to treat one arm with placebo because a potentially effective treatment would be denied to the patients. This study was The inclusion criteria for the participants in the study were being adults (>18 years old) hospitalized for at least seven days from the onset of COVID-19 symptoms, which is when usually began the inflammatory phase, with a diagnosis of pneumonia due to COVID-19 based on clinical-radiological criteria and a laboratory confirmed SARS-CoV-2 infection diagnosis, oxygen saturation <94% and 25(OH)D serum levels <30 ng/mL. Participants were excluded if they were lactating, pregnant women, were participating in other clinical trials with drugs with potential antiviral action for 

The analysis of the NK-mediated direct cell-mediated cytotoxicity (DCC) of PBMCs of the participants was performed using the NK-sensitive target K562 cell line as previously described 9 . K562 cells are lymphoblasts isolated from an individual with chronic myeloid leukemia that are used as specific targets of NK cells due to they do not express HLA Class I. Briefly, K562 cells were stained with PKH26 Red Fluorescence Cell Linker kit (Sigma Aldrich-Merck) and co-cultured 1:1 for 1 hour with PBMCs isolated from the patients. Cells were then collected and Annexin V conjugated with FITC (Thermofisher) was used to measure early apoptosis by flow cytometry. Data were acquired on BD LSRFortessa X-20 flow cytometer (BD Biosciences) and analyzed using Flow Jo software v10.0.7 (Tree Star Inc.).

In order to evaluate the specific antiviral DCC against SARS-CoV-2-infected cells of PBMCs from the participants in the study, the single-cycle pseudotyped virus pNL4-3Δenv_SARS-CoV-2-SΔ19(G614)_Ren was used to infect a monolayer of sensitive Vero E6 cells. This virus encodes SARS-CoV-2 spike glycoprotein, within the HIV-1 genome, as well as the Renilla luciferase gene generated as previously described 28, 29 .

Briefly, Vero E6 cells were infected with pNL4-3Δenv_ SARS-CoV-2-SΔ19(G614)_Ren (100 ng p24 Gag/well) for 48 hours. Cells were then washed and co-J o u r n a l P r e -p r o o f cultured for 1 hour with PBMC from the participants at a ratio of 1:2. PBMCs were collected and the cytotoxic cell populations were analyzed by flow cytometry. Vero E6 monolayer was dissociated from the plate with trypsin-EDTA solution (Sigma Aldrich-Merck, Darmstadt, Germany), and the caspase-3 activity was quantified by luminescence using Caspase-Glo 3/7 Analysis system (Promega) as a measurement of induction of apoptosis by the cytotoxic cells.

Categorical data were expressed as percentages, while the median was used to describe the central tendency of the non-normally distributed numerical data. Group comparisons were done using Mann-Whitney U-test or ordinary one-way ANOVA and Tukey's multiple comparisons test for numerical data and Chi-square (χ2) or Fisher's exact test for categorical data. All statistical analyses and graphics were performed using the GraphPad Prism software version 8.4.3 (GraphPad Software Inc., San Diego, California). P-values lower than 0.05 (two-tailed) were considered to be statistically significant.

A total of 86 patients were recruited for this study. Eighty-five participants fulfilled the inclusion criteria and agreed to participate in the study, and one patient was excluded from the study due to not being able to meet the study's schedule. After randomization, 41 patients received the supplementation of 10,000 IU/day (high dose) and 44 patients Table 1 ). In agreement with adequate randomization, we did not observe differences at baseline in demographic characteristics, vital signs, blood biochemistry data, distribution of ordinal scale scores, or treatments by group, although the levels of haemoglobin and bilirubin were significantly higher (p=0.006 and p= 0.010, respectively) in the group of participants who received 10,000 IU/day (Supplemental Table 1 ).

At the start of the study, mean serum 25(OH)D levels were 14 ng/ml (SD:6) in the group of patients who received 2,000 IU/day and 15 ng/ml (SD: 6) in the group who received 10,000 IU/day. After seven days of supplementation, the increase in serum vitamin D levels was 1.31-fold (p=0.0001) in the 10,000 IU/day group in comparison with the 2,000 IU/day group, and after 14 days the levels were increased 1.53-fold (p<0.0001) in the 10,000 IU/day group, in comparison with the 2,000 IU group/day. 

The participants who received 10,000 IU/day spent an average of 6.44 days in the hospital, while in the group of participants who received 2,000 IU/day the average LOS was 9.36 days, but there was no significant difference between both groups (Figure 2A ). 

During the study, 13 adverse effects were reported in the participants, of which 7 adverse effects occurred in the 2,000 IU/day group and 8 adverse effects occurred in the 10,000 IU/day group. However, none of these adverse events was directly linked to the Figure   3B ). Similarly, the levels of chemokine CCL3/MIP-1α were increased 1.12-fold (p=0.0021) after 14 days in the 10,000 IU/day group. There were no significant differences between groups for IL8-CXCL8 levels and for cytokines related to cellular activation such as GM-CSF, sCD25/IL-2Rα and sCD14 ( Figure 3C ). In the case of sCD14, the levels detected were higher than 20,000 pg/mL in some of the patients from both groups (normal values in the absence of infection <200 pg/ml).

On the other hand, the level of the anti-inflammatory cytokine IL-10 was increased 1.48-fold (p=0.0286) after 7 days in the 10,000 IU/day group in comparison with the 2,000 IU/day group ( Figure 4A ). Regarding the antiviral cytokines, the level of IFNγ was significantly increased 1.54-(p=0.0020) and 1.4-(p=0.0272) fold at 7 and 14 days, respectively, in the 10,000 IU/day group ( Figure 4B ). We did not find significant differences in the levels of IFN type I α and β between groups.

We randomly selected 8 participants from each group to evaluate the direct cytotoxic activity of PBMCs. When K562 cells were used as target, there was an increase of 1.5fold in the cytotoxic activity of PBMCs from participants who received 10,000 IU/day after 14 days of treatment, in comparison with the 2,000 IU/day group, but this was a non-significant trend ( Figure 5A Figure 5C , right graph). No significant differences were found in total levels of NKT cells or in the expression of CD107a between both groups of treatment ( Figure 5D ).

Interestingly, the expression of the NK cells inhibitory marker CD158f/KIR2DL5 was increased 2.2-fold (p=0.0078) in the PBMCs of participants from the group treated with 2,000 IU/day after 14 days of treatment, whereas it was less increased in the PBMCs of participants treated with 10,000 IU/day (1.7-fold; p=0.0078) ( Figure 5E ).

There were no significant differences between both groups in the total count of CD8+ T cells, the distribution of memory subpopulations, or the levels of CD3+CD8±TCRδγ+ T cells (Supplemental Figure 1 ).

Distribution of CD4+ T cell subpopulations CD4+ T cell levels significantly increased 1.31-fold (p=0.0464) after 7 days of supplementation with 10,000 IU/day of vitamin D ( Figure 6A ). In this group, TCM CD4+ T cells were increased 1.42-fold (p=0.0053) whereas effector CD4+ T cells such as TEMRA were reduced 2.5-fold (p=0.0051) after 7 days of treatment ( Figure 6B ). No significant differences were found between both groups in the levels of Tregs ( Figure   6C ).

North-South gradient that may be explained by the high prevalence of older people in Northern European populations, who are predisposed to a higher probability of cardio-pulmonary and metabolic comorbidities 30 . However, countries such as Italy or Spain have also shown high mortality rates, suggesting that other risk factors might also contribute to COVID19 infection severity 31 . Due to the immunomodulatory effect of vitamin D, its deficiency may contribute to airway and gastrointestinal infectious diseases, and it has been suggested as an additional risk factor associated with COVID-19 severity and mortality 25, 27 , although there is a great controversy about the effect of vitamin D supplementation during COVID-19 [32] [33] [34] [35] . Though Spain is a country with adequate sunlight, some studies describe that vitamin D intake is lower than the recommended levels of 10 µg/day 36 , resulting in a high proportion of the Spanish population with deficient levels of vitamin D 37 . In our study, the majority (81.7%) of participants who were hospitalized due to severe COVID-19 showed 25(OH)D serum levels in a deficient range (<20 ng/mL) 38 appointed as a potential prognostic marker of disease severity in these patients, as it would indicate the progression to the inflammatory form of the disease 43, 44 . Therefore, this inflammatory process that is developed during COVID-19 could be responsible for the impairment in achieving the primary endpoint of >30ng/ml in most participants, even with the higher dose of 10,000 IU/day. The severe and critical presentations of COVID-19 are characterized by an enhanced inflammatory response 3, 6 . Consequently, the administration of corticosteroids has been one of the most effective treatments since the beginning of the pandemic 45 .

Although with a much more modest effect, vitamin D has a immunomodulatory role that may favour an anti-inflammatory environment 46 , mostly based on the inhibition of the production of interleukins responsible for Th1 and Th17 polarization, which is characterized by the release of pro-inflammatory cytokines such as IL-6 and TNFα 47 . In our pilot study, we did not find significantly increased levels of pro-inflammatory cytokines in the plasma of those individuals who developed ARDS, despite both events J o u r n a l P r e -p r o o f are usually related during COVID-19 48 This could be due to the levels of cytokines are frequently higher in the lungs than in plasma and do not often correlate 49 . Therefore, the daily supplementation with a high dose of cholecalciferol did not reduce significantly the levels of inflammatory markers in plasma that had been already released, not even in individuals with ARDS, in accordance with previous studies 50 .

However, the participants who received the supplementation of 10,000 IU/day of cholecalciferol showed a significant increase in plasma of the anti-inflammatory cytokine IL-10, which may contribute to reduce the signs and symptoms of the disease related to the inflammatory environment. This result corroborated other studies that also described a significant increase in IL-10 levels after the administration of vitamin D 51, 52 . Therefore, the supplementation with vitamin D could at least partially contribute to reducing the inflammatory environment characteristic of COVID-19, which may also be related with the shortening of the length of the hospital stay observed in those participants supplemented with 10,000 IU/day of vitamin D who developed ARDS during the study. Although the number of participants who developed ARDS was quite reduced in our cohort, the improvement in the clinical recovery and the shortening of the stay at the hospital has also been described for individuals who received 50,000 IU/day of cholecalciferol for five days 53 .

On the other hand, COVID-19 is characterized by causing CD4+ T cell lymphopenia, which may be involved in the progression to more severe forms of the disease 54 . Although vitamin D may affect T-cell proliferation by interfering with the production of IL-2 55 , in our study, the CD4 count was significantly higher in patients treated with 10,000 IU/day for 7 days, which has also been described in patients with inflammatory diseases who receive vitamin D supplementation 56 . Moreover, those participants from our cohort who received 10,000 IU/day showed significantly J o u r n a l P r e -p r o o f enhanced levels of long-lived CD4+ TCM cell subpopulation and reduced levels of CD4+ TEMRA cells, which are short-lived cells that die upon activation 57 during protective immunity against pathogens 58 . Therefore, the reduced levels of CD4+ TEMRA cell subpopulation observed in those participants who received 10,000 IU/day may be a consequence of an increased antiviral activity. In fact, we also observed a significant increase in the production of IFNγ in the participants who received 10,000 IU/day after 7 days that was maintained after 14 days of treatment, which corroborated other studies that reported a significant increase of IFNγ levels after the administration of vitamin D 51, 52 . Therefore, supplementation with vitamin D could also be beneficial to induce a higher antiviral effect. Although vitamin D supplementation did not modify the proliferative capacity of cell populations with cytotoxic activity such as NK or CD8+ T cells, we observed a significant increase in the cytotoxic activity on SARS-CoV-2-infected cells exerted by PBMCs from those participants who received 10,000 IU/day for 14 days. This antiviral activity seemed to rely mostly on NK cell-mediated cytotoxic response, due to the degranulation capacity of these cells increased after 14 days of receiving 10,000 IU/day. Interestingly, an impairment in the expression of the degranulation marker CD107a has been described in NK cells from patients with the most severe forms of COVID-19 59 , which appeared to be counteracted by treatment with vitamin D. We cannot rule out that vitamin D was also promoting a similar effect on CD8+ T cells because there are precedents that deficiency in vitamin D receptor gene (Vdr-/-) may cause an impairment in the cytotoxic response against viral infections, reducing the diversity of effector CD8+ T cell repertoire and the survival of antigen-specific cytotoxic clones after viral clearance 60 .

In conclusion, the efficacy of vitamin D supplementation in patients with COVID-19 is still controversial [32] [33] [34] [35] 

We greatly appreciate all the patients for their participation in this study. We thank the excellent secretarial assistance of Mrs Olga Palao at the Centro Nacional de Drug Cholecalciferol (vitamin D) used in the study was donated by Italfarmaco Group (Cholecalciferol 25,000IU/2,5ml oral solution). Italfarmaco Group had no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or the preparation, review, or approval of the manuscript.

The authors declare no conflict of interest.

MCer and MCo conceptualized the project. MT, GC and MCo wrote the manuscript. 

Characteristics of SARS-CoV-2 and COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 with Different Severities: A Multicenter Study of Clinical Features

Inhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation Syndrome

Immunopathology of Hyperinflammation in COVID-19

Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Impaired Cytotoxic Response in PBMCs From Patients With COVID-19

Admitted to the ICU: Biomarkers to Predict Disease Severity

One year update on the COVID-19 pandemic: Where are we now?

Molecular immune pathogenesis and diagnosis of COVID-19

Scientific evidence in the COVID-19 treatment: A comprehensive review

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Dexamethasone in Hospitalized Patients with Covid-19

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients

Antiviral pills could change pandemic's course

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions

Vitamin D in autoimmunity: Molecular mechanisms and therapeutic potential

Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Lung-Centric Inflammation of COVID-19: Potential Modulation by Vitamin D

Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory

Vitamin D in Host Defense: Implications for Future Research

Preventing a covid-19 pandemic

Vitamin D and COVID-19 infection and mortality in UK Biobank

The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality

A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Explaining among-country variation in COVID-19 case fatality rate

Perspective: Vitamin D deficiency and COVID-19 severity -plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis

Insufficient evidence for vitamin D use in COVID-19: A rapid systematic review

Association of vitamin D status with COVID-19 and its severity

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Vitamin D and coronavirus disease 2019 (COVID-19): rapid evidence review

Reported Dietary Intake, Disparity between the Reported Consumption and the Level Needed for Adequacy and Food Sources of Calcium, Phosphorus, Magnesium and Vitamin D in the Spanish Population: Findings from the ANIBES Study †

Deficiencia de vitamina D en España: ¿realidad o mito?

Recomendaciones de la SEIOMM en la prevención y tratamiento del déficit de vitamina D

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial

Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial

Low Serum Levels of 25-Hydroxyvitamin D Accompany Severe COVID-19 Because it is a Negative Acute Phase Reactant

Blood vitamin concentrations during the acute-phase response

COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis

Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes. Front

Dexamethasone in Hospitalized Patients with Covid-19

Vitamin D: modulator of the immune system

Phenotypic and functional markers for 1α,25-dihydroxyvitamin D3-modified regulatory dendritic cells

Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration

COVID-19: Lung-Centric Immunothrombosis

Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression

High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients

Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFNγ levels and cathelicidin expression

Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Vitamin D and 1,25(OH)2D Regulation of T cells

Vitamin D3 treatment of Crohn's disease patients increases stimulated T cell IL-6 production and proliferation

Reduced CD4+ terminally differentiated effector memory T cells in moderate-severe house dust mites sensitized allergic rhinitis patients

Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Vitamin D Receptor Signals Regulate Effector and Memory CD8 T Cell Responses to Infections in Mice

Potential impact of maternal vitamin D status on peripheral blood and endometrium cellular immunity in women with recurrent implantation failure

Effects of Vitamin D3, Calcipotriol and FTY720 on the Expression of Surface Molecules and Cytolytic Activities of Human Natural Killer Cells and Dendritic Cells

Differential effect of dietary vitamin D supplementation on natural killer cell activity in lean and obese mice

MCo wrote the manuscript. MT, GC and LV performed the study of cytotoxicity

SRM performed the analysis of cell populations by flow cytometry with technical assistance from EM

MRLH and GC performed the analysis of cytokines in plasma

FR and EM processed and stored all blood samples

MCer identified, selected, and recruited the patients, and also collected the blood samples

MCer and MRLH collected and analyzed the clinical data